TRCT
STLN

Tower Research Capital (TRC)’s Starling Oncology STLN Stock Holding History

Tower Research Capital (TRC)’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.3K Sell
6,681
-633
-9% -$2.66K ﹤0.01% 3011
2026
Q1 		$22.5K Buy
7,314
+1,967
+37% +$6.03K ﹤0.01% 3401
2025
Q4 		$19K Sell
5,347
-8,286
-61% -$30.7K ﹤0.01% 3134
2025
Q3 		$47.6K Buy
13,633
+5,984
+78% +$20.5K ﹤0.01% 2560
2025
Q2 		$15.7K Sell
7,649
-1,894
-20% -$4.74K ﹤0.01% 3803
2025
Q1 		$10.9K Sell
9,543
-3,997
-30% -$3.09K ﹤0.01% 3599
2024
Q4 		$4.18K Buy
13,540
+4,741
+54% +$1.23K ﹤0.01% 4500
2024
Q3 		$2.88K Sell
8,799
-1,033
-11% -$428 ﹤0.01% 4930
2024
Q2 		$4.52K Buy
9,832
+2,080
+27% +$1.77K ﹤0.01% 4772
2024
Q1 		$12.2K Sell
7,752
-4,294
-36% -$8.16K ﹤0.01% 3494
2023
Q4 		$24.6K Buy
+12,046
New +$20.9K ﹤0.01% 3531
2023
Q3 		– Sell
-3,640
Closed -$2K – 6235
2023
Q2 		$2K Sell
3,640
-11,041
-75% -$5.84K ﹤0.01% 5275
2023
Q1 		$10K Buy
14,681
+7,660
+109% +$9.77K ﹤0.01% 4410
2022
Q4 		$12K Buy
7,021
+5,345
+319% +$15K ﹤0.01% 3753
2022
Q3 		$8K Sell
1,676
-2,012
-55% -$11.8K ﹤0.01% 4813
2022
Q2 		$19K Buy
3,688
+2,873
+353% +$20.9K ﹤0.01% 3861
2022
Q1 		$6K Buy
815
+615
+308% +$4.15K ﹤0.01% 4930
2021
Q4 		$2K Sell
200
-252
-56% -$2.24K ﹤0.01% 5669
2021
Q3 		$4K Buy
+452
New +$4.49K ﹤0.01% 4999
2021
Q2 		– Sell
-49
Closed – – 5845
2021
Q1 		$0 Buy
49
+48
+4,800% +$511 ﹤0.01% 5728
2020
Q4 		$0 Buy
+1
New +$10 ﹤0.01% 5408

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Tower Research Capital (TRC)'s STLN Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Starling Oncology (STLN) stake by 8.7% in Q2 2026, selling an estimated $2.66K and leaving 6,681 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3011.

Tower Research Capital (TRC) first reported a position in STLN in Q4 2020 and has held it in 21 quarters since. The position peaked at $47.6K in Q3 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Tower Research Capital (TRC) held 6,681 shares of Starling Oncology worth $36.3K as of Q2 2026.
  • Tower Research Capital (TRC) sold 633 Starling Oncology shares in Q2 2026, an estimated $2.66K.
  • Starling Oncology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3011 holding.
  • Tower Research Capital (TRC) first reported a position in Starling Oncology in Q4 2020 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Starling Oncology position peaked at $47.6K in Q3 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.